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For the past several years, Dr. Suk's research focused on brain glial cells and neuroinflammation. Non-neuronal glial cells produce specific neurotransmitters and proteins under various physiological and pathological conditions to influence the survival and functions of neighboring neurons and glia in the central nervous system (CNS). Dr. Suk's lab is interested in these proteins secreted from glial cells. A long-term goal of the lab is to identify and functionally characterize glial secretory proteins with respect to brain health and disease. Lipocalin-2, prostaglandin D2 synthase, and pentraxin-3 are a few examples of glial secretory proteins that the lab has been studying for several years. Dr. Suk's findings based on *in vitro* and *in vivo* experiments as well as the analyses of clinical samples led to the discovery of potential biomarkers and drug targets for the acute CNS injuries and chronic disorders such as Alzheimer's disease, vascular dementia, Parkinson's disease, multiple sclerosis, and pathological pain. On-going works in the lab are now focused on the potential role of glial secretions in regulating the CNS functions from the physiological perspective. Glia-oriented omics approaches and large-scale experiments are also being employed to better understand a big picture of neuroinflammation and to uncover new drug targets for the devastating diseases in the CNS.
